World journal of oncology · 2026
Siglec-15 Expression in Gastric Carcinoma and Its Association With Clinicopathological Variables.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al Badr Sara, Battah Abdelkader, Alsughayer Ahmad, Alsmarat Fanar, Halahleh Khalid, Sughayer Maher
Аннотация
BACKGROUND: Gastric cancer remains the fifth most common malignancy worldwide and is often diagnosed at advanced stages with limited treatment options. Although immunotherapy targeting the programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) has improved outcomes in several cancers, many patients exhibit resistance, necessitating alternative therapeutic strategies. Sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15), a recently recognized immune suppressor, is overexpressed in tumor cells and tumor-associated macrophages (TAMs), and is largely absent from normal tissues, making it a promising immunotherapy target.
METHODS: This tissue microarray (TMA) study retrospectively collected formalin-fixed paraffin-embedded (FFPE) tissue specimens from 2015 to 2019 for 77 gastric cancer patients from King Hussein Cancer Center. Siglec-15 expression patterns in tumor cells and TAMs were analyzed and compared with clinicopathological features and patient outcomes. Survival was assessed using Kaplan-Meier analysis.
RESULTS: Siglec-15 expression was detected in 50.7% of tumor samples and 36.4% of TAMs. Membranous expression was significantly associated with tumor differentiation, with higher expression observed in moderately differentiated tumors (P = 0.048), while cytoplasmic and TAM expression showed no significant associations with clinical variables. Although not statistically significant, positive Siglec-15 expression-both membranous and cytoplasmic-was associated with shorter median overall survival (cytoplasmic: 30.62 vs. 74.92 months, P = 0.1790; membranous: 39.44 vs. 66.07 months, P = 0.5761). Established prognostic indicators such as age, clinical stage, and pT stage were significantly associated with overall survival.
CONCLUSION: Siglec-15 is frequently expressed in gastric cancer and may contribute to immune evasion within the tumor microenvironment. Although no significant association with prognosis was found, its high expression underscores its potential as a novel immunotherapeutic target. Further studies are warranted to validate these findings and explore Siglec-15 clinical utility.
METHODS: This tissue microarray (TMA) study retrospectively collected formalin-fixed paraffin-embedded (FFPE) tissue specimens from 2015 to 2019 for 77 gastric cancer patients from King Hussein Cancer Center. Siglec-15 expression patterns in tumor cells and TAMs were analyzed and compared with clinicopathological features and patient outcomes. Survival was assessed using Kaplan-Meier analysis.
RESULTS: Siglec-15 expression was detected in 50.7% of tumor samples and 36.4% of TAMs. Membranous expression was significantly associated with tumor differentiation, with higher expression observed in moderately differentiated tumors (P = 0.048), while cytoplasmic and TAM expression showed no significant associations with clinical variables. Although not statistically significant, positive Siglec-15 expression-both membranous and cytoplasmic-was associated with shorter median overall survival (cytoplasmic: 30.62 vs. 74.92 months, P = 0.1790; membranous: 39.44 vs. 66.07 months, P = 0.5761). Established prognostic indicators such as age, clinical stage, and pT stage were significantly associated with overall survival.
CONCLUSION: Siglec-15 is frequently expressed in gastric cancer and may contribute to immune evasion within the tumor microenvironment. Although no significant association with prognosis was found, its high expression underscores its potential as a novel immunotherapeutic target. Further studies are warranted to validate these findings and explore Siglec-15 clinical utility.